Nuvo Research has enrolled the first patient in its European Phase II clinical trial evaluating the immune modulating drug candidate WF10 for the treatment of allergic rhinitis, also known as hay fever.
The trial, which will enroll 50 patients, will assess the efficacy and safety of WF10 infusions for patients with severe persistent allergic rhinitis.
Go deeper with GlobalData
Patients who meet the trial criteria will be randomised into two groups – WF10 and placebo – and treatment will be administered once daily for five consecutive days, while the assessment will spread over a three-month period.
The trial is scheduled to be complete by early 2011.
The Canadian drug development firm is co-developing WF10 with the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig, Germany.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
